Amarin raises gross sales steering for coronary heart drug Vascepa, hires extra gross sales reps for bigger advertising push

Amarin (AMRN) pre-announced report quarterly gross sales of its coronary heart drug Vascepa on Tuesday and raised its monetary steering for the rest of the yr, citing sturdy affected person demand for the drug, derived from fish oil, now that it has been proven to considerably decrease the chance of loss of life and different adversarial cardiovascular occasions.

The Bedminster, New Jersey-based drug maker can be doubling the dimensions of its industrial salesforce to arrange for the extremely anticipated enlargement of Vascepa’s label by the Meals and Drug Administration in late September, the corporate stated. 

Gross sales of Vascepa within the just-ended second quarter reached a report vary of $97 million to $101 million, Amarin stated. The ultimate gross sales tally will likely be introduced after the corporate’s auditors evaluate the outcomes. 


On the $99 million midpoint, Vascepa gross sales within the second quarter practically doubled gross sales from the year-ago interval. Promote-side analysts, on common, have been anticipating Vascepa gross sales of $88 million within the third quarter, based on Koyfin.

Amarin attributes the accelerated gross sales progress of Vascepa to the publication final yr of outcomes from the REDUCE-IT scientific trial, which discovered that Vascepa offers vital cardiovascular advantages to a much wider swath of individuals than beforehand believed. 

Primarily based on surging demand for Vascepa prescriptions, Amarin now expects 2019 gross sales within the vary of $380 to $420 million, the corporate stated. Its earlier Vascepa gross sales steering, provided final January, was $350 million. 

The present analyst consensus has Vascepa gross sales reaching $365 million in 2019, based on Koyfin.

The FDA is predicted to rule by Sept. 28 on Amarin’s request to broaden the Vascepa label to incorporate the guts profit claims ensuing from the REDUCE-IT scientific trial. To this point, the FDA has nonetheless not knowledgeable Amarin about any plans to convene an outdoor advisory committee assembly to evaluate the Vascepa knowledge, the corporate stated Tuesday. 

Sometimes, the FDA provides a drugmaker 60 days advance discover to arrange for an advisory committee assembly. With the calendar turning over to July, the chances that the FDA will schedule a Vascepa assembly are rising smaller, which in flip, makes it extra seemingly that the company will approve the Vascepa label enlargement at once. 

Medical doctors are already prescribing extra Vascepa based mostly on the publication of the guts advantages seen within the REDUCE-IT research. Amarin’s advertising efforts, nonetheless, should await an official inexperienced gentle from the FDA. In anticipation of that occuring, the corporate stated Tuesday it has begun hiring new salespeople to market Vascepa. As soon as totally employed, Amarin’s industrial staff will complete 800 individuals, double its present measurement. 

Amarin additionally intends to submit a advertising utility for Vascepa in Europe by the top of the yr.

Shares of Amarin rose 9% to $21 in early buying and selling.